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Resistant somatoform symptoms:
Try CBT and antidepressants
reatment-resistant somatoform disorders
are chronic (duration >1 year), can cause
significant functional impairment, and respond
poorly to routine care.
In the somatoform category, DSM-IV-TR in-
cludes diverse diagnoses such as conversion disor-
der, hypochondriasis, pain disorder, and body dys-
morphic disorder. But like mismatched shoes,
these disorders do not fit together well—one rea-
son they are often misdiagnosed and ineffectively
treated. This article describes:
• debate about how to categorize somatoform
disorders—as psychological or physiologic
• evidence supporting psychotherapy and anti-
depressants to help patients with treatment-
resistant somatoform disorders.
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WHICH CATEGORY?
Somatoform disorders are common in primary care.
A medical utilization survey of 1,500 primary care
patients found somatization symptoms in >20%.3
Controlling for comorbid psychiatric or medical
illness did not change the study’s findings, which
suggests that somatization is a distinct entity and
not a symptom of another underlying disorder.
Little is known about somatoform disorders’
pathophysiology (Box 1),1 but their unifying theme
is that psychological factors contribute to, amplify,
or alter the presentation of physical illness. Not
only do these disorders not form a coherent DSM
category, but—as described by Mayou et al2—
the lack of clearly defined thresholds between
normal and pathologic behaviors is one of
numerous problems that complicate diagnosis
and treatment (Box 2, page 107).
Psychosomatic diad. Despite DSM-IV’s claims to
etiologic neutrality, the origin of somatoform disor-
ders’ physical symptoms clearly is meant to be psy-
chological. As Lipowski4 said, somatization is “a
tendency to experience and express somatic distress
and symptoms unaccounted for by pathological
findings, to attribute them to physical illness, and
to seek medical help for them. It is often assumed
that somatization becomes manifest in response to
psychosocial stress brought about by life events that
are personally stressful to the individual.” 
Kroenke and others,5,6 however, have pointed
out 2 shortcomings of this definition:
• the difficulty in knowing when a physical
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Somatoform disorders: Interacting psychiatric and biologic processes
Box 1 
Psychobiologic causes of somatoform disorders
are poorly understood. In a recent review, Rief
and Barsky1 emphasized that somatoform
symptoms such as abdominal pain, headaches,
or dizziness “are not strictly mental events, but
are associated with a diversity of biological
processes.” They propose that the following factors
might contribute to somatoform disorders.
Autonomic physiologic arousal may lead
patients to misperceive the meaning of normal
bodily symptoms, but most studies have been
equivocal or correlate closely with changes in
the cardiovascular system. For example, patients
with somatoform spectrum disorders who
performed mentally distressing tasks did not
have the same decrease in heart rate after
completing the task as normal controls did,
suggesting a deficit in autonomic reactivity.
Hypothalamic-pituitary-adrenal (HPA) axis
studies also have been equivocal. Some have
found low cortisol in patients with somatoform
disorders—suggesting commonalities with
conditions such as posttraumatic stress disorder
—but other studies have found normal or even
elevated cortisol. Although a relationship
between the HPA axis and somatoform disorders
is likely, its nature remains unclear or may be
indirect. 
Serotonin is known to alter pain perception
in major depressive disorder, so this
neurotransmitter also probably plays a role
in somatoform disorders. Low serotonin—
mediated in part by alterations in branched-
chain amino acid concentration—may be linked
to increased pain perception.
Perception and filtering of body signals. A
signal-filtering model of somatoform symptoms
proposes that physical sensations enter
consciousness influenced by numerous factors.
These signals are then sent to a filter system,
which itself is subject to factors that may
decrease its activity. Cortical perception
of distress may occur and symptoms begin
to manifest if enough factors come into play.
cont inued on page 107
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this diagnostic category. Tyrer8 reviewed his clini-
cal experience and reported shifting from a view
that people with excessive pain had a psychiatric
disorder to the view that living with chronic pain
produces a profile similar to that of a person with a
psychiatric disorder. 
Physiologic component. Others recommend caution
before radically altering DSM’s categorizations.
Rather than shift symptoms to Axis III—as
Kroenke suggests—Starcevic9 would use unex-
plained physical symptoms as an organizing prin-
ciple and group disorders with common features,
such as somatization disorder, conversion disorder,
pain disorder, and undifferentiated somatoform
symptom truly is unexplained, especially
in patients with comorbid medical illness5
• the instability of somatoform diagnoses
(in a cohort examined with the same
questionnaire 12 months apart, 43% of
“lifetime somatic symptoms” patients
reported at the first screening were not
reported at the second).6
Kroenke5 suggests using “physical symp-
tom disorder” as an etiologic-neutral descrip-
tor of unexplained physical symptoms. He
would place this category on Axis III and shift
the causal emphasis from psychological to
unexplained. This category would replace som-
atization disorder, undifferentiated somato-
form disorder, and pain disorder in DSM. 
Similarly, Mayou et al2 contend that
because most patients with somatoform disor-
ders are treated by primary care physicians,
having their disorders understood as psychi-
atric does not serve them well.
Psychiatric component. Conversely, patients
with somatization disorder often have psycho-
logical symptoms, and many have personality
disorders. The number of somatic symptoms
with unexplained cause may be a normally dis-
tributed trait, with somatization disorders at
the extreme end of the spectrum. Thus:
• Hypochondriasis could be reconsidered as
health anxiety disorder because it features
anxiety about potential illness.2
• Conversion disorders might be regrouped
with other disorders focused on dissociation.2
• Body dysmorphic disorder might be re-
grouped with obsessive-compulsive disorder.7
These changes would shift focus away from
the disorders’ physiologic presentations, empha-
size the psychiatric disorders to which they likely
are related, and provide insight into treatments
and clinical investigations.
Pain disorder could be removed from DSM
because of persistent concerns about the validity of
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Problems with DSM categorization
of somatoform disorders
Box 2
• Somatoform disorders lack clearly defined
thresholds that establish a difference between
normal and pathologic behaviors
• Somatoform disorders do not form a coherent
category, and exclusion criteria are ambiguous 
• By existing, the category suggests that some
disorders are physical and others are mental,
leaving little room for intermediate or mixed
conditions 
• Patients reject the term “somatoform”
because it conveys doubt about the reality
of their conditions 
• Somatoform disorders are incompatible with
some cultures’ views of mental illness (for
example, the DSM translation used in China
does not include the somatoform category)
• Nonspecific somatoform illness subcategories
cannot achieve established reliability standards
in studies examining diagnoses
• Medical-legal cases and insurance entitlements
are complicated by unclear descriptions
of somatoform disorders
Source: Reference 2
cont inued f rom page 102
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disorder. Body dysmorphic disorder and hypochon-
driasis—focusing on dysfunctional appraisal of
physical symptoms—would likely move elsewhere.
Hiller and Rief 10—who advocate strongly for
keeping somatoform disorders in DSM—suggest 4
categories: monosymptomatic, polysymptomatic,
hypochondriasis, and body dysmorphic disorder.
They believe grouping diagnoses in this way would
improve and refine existing nosology. 
NEW TREATMENT APPROACHES
As the categorization debate continues, a treat-
ment approach is developing that includes cogni-
tive-behavioral therapy (CBT) and antidepressants
to address the psychological and physiologic
effects of resistant somatoform disorders (Box 3).
Consultation letters. Sending a consultation letter to
the patient’s primary care physician is considered
the standard of care (Box 4, page 114).11 In the study
that introduced the consultation letter,12 patients
with somatization disorder were randomly
assigned to treatment (a consultation letter) or con-
trol (treatment as usual). Health care utilization
costs declined approximately 50%—largely
because of decreased hospitalization—when
patients’ physicians received consultation letters,
compared with no change for usual treatment.
Consultation letters may reduce health care
spending but are less effective in improving symp-
toms. Evidence is changing treatment as psycho-
therapies have been found to help patients with
somatoform disorders.
Group psychotherapy. In a controlled trial, primary
care patients with somatization disorder received
short-term group CBT or treatment as usual, with
follow-up 6 months later. Those in the CBT
group—who had received patient education and
relaxation training—showed moderate but signifi-
cant improvement in physical illness and somatic
preoccupation, hypochondriasis, and medication
use. Usual-care patients did not improve.13
CBT vs relaxation. A group of 191 inpatients
described as “highly impaired” by somatization
syndrome—≥8 DSM-IV somatoform symptoms—
was evaluated for psychopathology, subjective
health status, and life satisfaction. They then were
randomly assigned to somatization-focused CBT
(“soma”) or relaxation training and compared with
34 control patients. At 1-year follow-up, doctor
visits had declined significantly in patients who
received CBT (“soma”), and their somatoform
symptoms were reduced compared with controls’.11
Psychotherapy vs listening. In a randomized, con-
trolled trial, 102 patients with chronic refractory irri-
table bowel syndrome were assigned to receive
exploratory psychotherapy or supportive listening.
After 12 weeks, psychotherapy was more effective in
improving physical and psychological symptoms,
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Treatment approach to patients
with somatoform disorders
Box 3
• Carefully evaluate for mood, anxiety, 
and substance use disorders
• Assess over-the-counter, prescription, and
illicit drugs the patient may be using to
control pain and other physical symptoms
• Review medical and psychiatric records,
laboratory and radiographic findings  
• Discuss the patient's case with his or her
primary care physician, and provide formal
feedback or a consultation letter 
• Treat comorbid psychiatric disorders with
medications such as selective serotonin
reuptake inhibitors or venlafaxine, which
have improved somatoform symptoms
in randomized, controlled trials 
• Offer the patient cognitive-behavioral 
therapy (10 to 20 sessions) that focuses 
on reducing somatoform symptoms, and
advise the primary care provider to 
schedule monthly follow-up intervals
cont inued on page 113
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Dose Dependency of Adverse Events in Short-Term, Placebo-Controlled Trials—Extrapyramidal
Symptoms—In an acute-phase controlled clinical trial in schizophrenia, there was no significant
difference in ratings scales incidence between any dose of oral olanzapine (5+2.5, 10+2.5, or 15+2.5
mg/d) and placebo for parkinsonism (Simpson-Angus Scale total score >3) or akathisia (Barnes
Akathisia global score 2). In the same trial, only akathisia events (spontaneously reported COSTART
terms akathisia and hyperkinesia) showed a statistically significantly greater adverse events incidence
with the 2 higher doses of olanzapine than with placebo. The incidence of patients reporting any
extrapyramidal event was significantly greater than placebo only with the highest dose of oral
olanzapine (15+2.5 mg/d). In controlled clinical trials of intramuscular olanzapine for injection, there
were no statistically significant differences from placebo in occurrence of any treatment-emergent
extrapyramidal symptoms, assessed by either rating scales incidence or spontaneously reported
adverse events.
Other Adverse Events—Dose-relatedness of adverse events was assessed using data from a clinical
trial involving 3 fixed oral dosage ranges compared with placebo. The following treatment-emergent
events showed a statistically significant trend: asthenia, dry mouth, nausea, somnolence, tremor.
Vital Sign Changes—Oral olanzapine was associated with orthostatic hypotension and tachycardia in
clinical trials. Intramuscular olanzapine for injection was associated with bradycardia, hypotension, and
tachycardia in clinical trials (see PRECAUTIONS).
Weight Gain—In placebo-controlled 6-week schizophrenia studies, weight gain was reported in 5.6%
of oral olanzapine patients (average 2.8-kg gain) compared to 0.8% of placebo patients (average 0.4-kg
loss); 29% of olanzapine patients gained >7% of their baseline weight, compared to 3% of placebo
patients. During continuation therapy (238 median days of exposure), 56% of patients met the criterion
for having gained >7% of their baseline weight. Average gain during long-term therapy was 5.4 kg.
Laboratory Changes—Olanzapine is associated with asymptomatic increases in SGPT, SGOT, and
GGT and with increases in serum prolactin and CPK (see PRECAUTIONS). Asymptomatic elevation of
eosinophils was reported in 0.3% of olanzapine patients in premarketing trials. There was no indication
of a risk of clinically significant neutropenia associated with olanzapine in the premarketing database.
In clinical trials among olanzapine-treated patients with baseline random triglyceride levels of 
<150 mg/dL (N=659), 0.5% experienced triglyceride levels of 500 mg/dL anytime during the trials. In
these same trials, olanzapine-treated patients (N=1185) had a mean triglyceride increase of 20 mg/dL
from a mean baseline of 175 mg/dL. In placebo-controlled trials, olanzapine-treated patients with
baseline random cholesterol levels of <200 mg/dL (N=1034) experienced cholesterol levels of 
240 mg/dL anytime during the trials more often than placebo-treated patients (N=602; 3.6% vs 2.2%
respectively). In these same trials, olanzapine-treated patients (N=2528) had a mean increase of 
0.4 mg/dL in cholesterol from a mean baseline of 203 mg/dL, which was significantly different
compared to placebo-treated patients (N=1415) with a mean decrease of 4.6 mg/dL from a mean
baseline of 203 mg/dL.
ECG Changes—Analyses of pooled placebo-controlled trials revealed no statistically significant
olanzapine/placebo differences in incidence of potentially important changes in ECG parameters,
including QT, QTc, and PR intervals. Olanzapine was associated with a mean increase in heart rate of 
2.4 BPM compared to no change among placebo patients.
Other Adverse Events Observed During Clinical Trials—The following treatment-emergent events
were reported with oral olanzapine at multiple doses 1 mg/d in clinical trials (8661patients, 
4165 patient-years of exposure). This list may not include events previously listed elsewhere in labeling,
those events for which a drug cause was remote, those terms which were so general as to be
uninformative, and those events reported only once or twice which did not have a substantial probability
of being acutely life-threatening. Frequent events occurred in 1/100 patients; infrequent events
occurred in 1/100 to 1/1000 patients; rare events occurred in <1/1000 patients. Body as a Whole—
Frequent: dental pain, flu syndrome; Infrequent: abdomen enlarged, chills, face edema, intentional
injury, malaise, moniliasis, neck pain, neck rigidity, pelvic pain, photosensitivity reaction, suicide
attempt; Rare: chills and fever, hangover effect, sudden death. Cardiovascular—Frequent: hypotension;
Infrequent: atrial fibrillation, bradycardia, cerebrovascular accident, congestive heart failure, heart
arrest, hemorrhage, migraine, pallor, palpitation, vasodilatation, ventricular extrasystoles; Rare:
arteritis, heart failure, pulmonary embolus. Digestive—Frequent: flatulence, increased salivation, thirst;
Infrequent: dysphagia, esophagitis, fecal impaction, fecal incontinence, gastritis, gastroenteritis,
gingivitis, hepatitis, melena, mouth ulceration, nausea and vomiting, oral moniliasis, periodontal
abscess, rectal hemorrhage, stomatitis, tongue edema, tooth caries; Rare: aphthous stomatitis,
enteritis, eructation, esophageal ulcer, glossitis, ileus, intestinal obstruction, liver fatty deposit, tongue
discoloration. Endocrine—Infrequent: diabetes mellitus; Rare: diabetic acidosis, goiter. Hemic and
Lymphatic—Infrequent: anemia, cyanosis, leukocytosis, leukopenia, lymphadenopathy,
thrombocytopenia; Rare: normocytic anemia, thrombocythemia. Metabolic and Nutritional—
Infrequent: acidosis, alkaline phosphatase increased, bilirubinemia, dehydration, hypercholesteremia,
hyperglycemia, hyperlipemia, hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, lower
extremity edema, upper extremity edema; Rare: gout, hyperkalemia, hypernatremia, hypoproteinemia,
ketosis, water intoxication. Musculoskeletal—Frequent: joint stiffness, twitching; Infrequent: arthritis,
arthrosis, leg cramps, myasthenia; Rare: bone pain, bursitis, myopathy, osteoporosis, rheumatoid
arthritis. Nervous System—Frequent: abnormal dreams, amnesia, delusions, emotional lability,
euphoria, manic reaction, paresthesia, schizophrenic reaction; Infrequent: akinesia, alcohol misuse,
antisocial reaction, ataxia, CNS stimulation, cogwheel rigidity, delirium, dementia, depersonalization,
dysarthria, facial paralysis, hypesthesia, hypokinesia, hypotonia, incoordination, libido decreased, libido
increased, obsessive compulsive symptoms, phobias, somatization, stimulant misuse, stupor,
stuttering, tardive dyskinesia, vertigo, withdrawal syndrome; Rare: circumoral paresthesia, coma,
encephalopathy, neuralgia, neuropathy, nystagmus, paralysis, subarachnoid hemorrhage, tobacco
misuse. Respiratory—Frequent: dyspnea; Infrequent: apnea, asthma, epistaxis, hemoptysis,
hyperventilation, hypoxia, laryngitis, voice alteration; Rare: atelectasis, hiccup, hypoventilation, lung
edema, stridor. Skin and Appendages—Frequent: sweating; Infrequent: alopecia, contact dermatitis,
dry skin, eczema, maculopapular rash, pruritus, seborrhea, skin discoloration, skin ulcer, urticaria,
vesiculobullous rash; Rare: hirsutism, pustular rash. Special Senses—Frequent: conjunctivitis;
Infrequent: abnormality of accommodation, blepharitis, cataract, deafness, diplopia, dry eyes, ear pain,
eye hemorrhage, eye inflammation, eye pain, ocular muscle abnormality, taste perversion, tinnitus;
Rare: corneal lesion, glaucoma, keratoconjunctivitis, macular hypopigmentation, miosis, mydriasis,
pigment deposits lens. Urogenital—Frequent: vaginitis*; Infrequent: abnormal ejaculation,*
amenorrhea,* breast pain, cystitis, decreased menstruation,* dysuria, female lactation,* glycosuria,
gynecomastia, hematuria, impotence,* increased menstruation,* menorrhagia,* metrorrhagia,*
polyuria, premenstrual syndrome,* pyuria, urinary frequency, urinary retention, urinary urgency,
urination impaired, uterine fibroids enlarged,* vaginal hemorrhage*; Rare: albuminuria, breast
enlargement, mastitis, oliguria. (*Adjusted for gender.) 
The following treatment-emergent events were reported with intramuscular olanzapine for injection
at one or more doses 2.5 mg/injection in clinical trials (722 patients). This list may not include events
previously listed elsewhere in labeling, those events for which a drug cause was remote, those terms
which were so general as to be uninformative, and those events reported only once or twice which did
not have a substantial probability of being acutely life-threatening. Body as a Whole—Frequent:
injection site pain; Infrequent: abdominal pain, fever. Cardiovascular—Infrequent: AV block, heart
block, syncope. Digestive—Infrequent: diarrhea, nausea. Hemic and Lymphatic—Infrequent: anemia.
Metabolic and Nutritional—Infrequent: creatine phosphokinase increased, dehydration, hyperkalemia.
Musculoskeletal—Infrequent: twitching. Nervous System—Infrequent: abnormal gait, akathisia,
articulation impairment, confusion, emotional lability. Skin and Appendages—Infrequent: sweating.
Postintroduction Reports—Reported since market introduction and temporally (not necessarily
causally) related to olanzapine therapy: allergic reaction (eg, anaphylactoid reaction, angioedema,
pruritus or urticaria), diabetic coma, jaundice, pancreatitis, priapism, rhabdomyolysis, and venous
thromboembolic events (including pulmonary embolism and deep venous thrombosis). Random
cholesterol levels of 240 mg/dL and random triglyceride levels of 1000 mg/dL have been rarely reported.
DRUG ABUSE AND DEPENDENCE: Olanzapine is not a controlled substance. 
ZYPREXA is a registered trademark of Eli Lilly and Company. ZYDIS is a registered trademark of
Cardinal Health, Inc. or one of its subsidiaries.
Literature revised March 20, 2006
PV 5195 AMP
Eli Lilly and Company
Indianapolis, IN 46285, USA
www.ZYPREXA.com
ZYPREXA Olanzapine Tablets
ZYPREXA ZYDIS Olanzapine Orally Disintegrating Tablets
ZYPREXA IntraMuscular Olanzapine for Injection PV 5195 AMP 113
although the difference was statistically significant
only in women. After 1 year, patients who received
psychotherapy remained well and control patients
who declined psychotherapy had relapsed.14
CBT vs usual treatment. In a randomized controlled
trial, 84 patients with somatization disorder
received 10 CBT sessions or treatment as usual.
CBT’s goals were to:
• reduce physiologic arousal though relaxation
techniques
• enhance activity regulation through increas-
ing exercise and meaningful pleasurable
activities and pacing activities
• increase awareness of emotions
• modify dysfunctional beliefs
• enhance communication of thoughts and
emotions
• reduce spousal reinforcement of illness
behavior. 
The Clinical Global Impression Scale for
Somatization Disorder showed significantly
greater improvement in the group receiving CBT.
Somatic symptoms as measured by patients’ self-
ratings also improved more in the CBT group.15
Psychotherapy’s success in these and other
studies supports the idea that somatoform spec-
trum disorders resemble other conditions—such as
mood and anxiety disorders—that respond to psy-
chological treatment.
ANTIDEPRESSANT THERAPY
Controlled trials also have shown that some antide-
pressants are more effective than placebo in
improving somatoform symptoms.
St. John’s wort. In a randomized, placebo-controlled,
double-blind trial, 184 patients with somatoform
disorders but not major depression received St.
John’s wort extract, 300 mg bid, or placebo. After
6 weeks, 45% of patients responded to St. John’s
wort, compared with 21% for placebo (P=0.0006).
Six measures determined response; St. John’s wort
and placebo were equally well tolerated.16
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Extended-release venlafaxine. A pilot study en-
rolled 112 adult primary care patients with multi-
somatoform disorder (≥3 medically unexplained,
bothersome physical symptoms plus ≥2-year histo-
ry of somatization) and comorbid major depressive
disorder, generalized anxiety disorder, or social
anxiety disorder. Patients were randomly assigned
to double-blind treatment with venlafaxine ER,
≤225 mg/d (n=55), or placebo (n=57).
Primary outcome was change in the 15-item
Patient Health Questionnaire (PHQ-15) somatic
symptom severity score. After 12 weeks, PHQ-
15 scores declined significantly (P <0.0001) in
both groups but did not improve significantly
more with venlafaxine ER than with placebo 
(-8.3 vs -6.6, respectively, P=0.097). Among sec-
ondary measures, venlafaxine ER was more effec-
tive than placebo in improving bodily pain
(P=0.03), physical symptoms (P=0.02), and anx-
iety (P=0.02).17
Citalopram. In an 8-week trial, investigators com-
pared the efficacy of a selective serotonin reuptake
inhibitor (SSRI) and a selective noradrenaline
reuptake inhibitor (SNRI) on pain symptoms in
35 patients with somatoform pain disorder.
Patients were randomly assigned to double-blind
treatment with the SSRI citalopram, 40 mg/d
(n=17), or the SNRI reboxetine, 8 mg/d (n=18).
In patients receiving citalopram, scores de-
creased significantly from baseline on the Present
Pain Intensity scale (3.5 vs 2.8, P=0.045) and
Total Pain Rating Index of the McGill Pain
Questionnaire (41.9 vs 30, P=0.004), but these
scores did not change significantly in patients
receiving reboxetine. Depression symptoms, as
measured by the Zung Self-Rating Depression
Scale, did not change significantly in either group.
The authors concluded that citalopram was
moderately effective for somatoform pain disor-
der in this small trial. Although antidepressants’
efficacy for somatoform symptoms may be medi-
ated through changes in comorbid mood and
anxiety disorders, these authors observed that
citalopram’s analgesic effect appeared to be inde-
pendent of how patients rated their depressive
symptoms.18
TREATMENT RECOMMENDATIONS
Based on the evidence and our experience, we rec-
ommend offering CBT to patients with recent
symptom onset and insight into their comorbid
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Somatoform disorders are often 
undiagnosed and difficult to treat.
Improved diagnostic criteria and better
collaboration with primary care may lead
to better outcomes and more evidence-
based treatment. Cognitive-behavioral
therapy and pharmacotherapy are
emerging treatment options for patients
with refractory illness. 
Consultation letter for somatization:
Discourage saying ‘it’s in your head’
Box 4
Describe somatoform disorder, its relapsing
course, and low morbidity and mortality rates 
Encourage the primary care physician to:
• serve as the patient’s primary doctor
and avoid fragmented care from
numerous sources 
• schedule regular appointments with
the patient 
• perform physical exams at each visit 
• eliminate unnecessary tests or
hospitalizations
• avoid statements such as “it’s all in your
head” when medical tests are negative 
Source: Reference 13
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mood and anxiety disorders. If the patient does not
improve after 8 to 12 sessions, consider adding an
antidepressant such as:
• citalopram, 20 to 60 mg/d
• venlafaxine XR, 150 to 375 mg/d.
For patients with chronic somatization, start
with combined pharmacotherapy and CBT. 
Side effects are a frequent concern in this patient
population, so titrate dosages slowly. Aim for the
target antidepressant dosages used to treat major
depression, and avoid declaring a treatment failure
without first completing adequate trials. Once the
patient is stable on medication, continue for a least
1 somatization-free year. 
Allow patients to discuss their physical concerns,
and attempt to support them in their suffering. At
the same time, help them focus on attaining real-
istic goals for occupational and social functioning.
Work closely with the primary care provider in
treatment planning to avoid sending the patient
mixed messages. Communicating in the spirit of
respect and collaboration with primary care col-
leagues can help prevent “splitting,” in which the
patient may come to idealize one practitioner and
devalue the other.  
Remember that patients with somatization can
become medically ill. Remind their primary care
providers to perform expected evaluations as dic-
tated by objective findings. 
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